SA Asks: What’s the most attractive weight-loss stock right now?

While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near commercialization.

Currently, nearly a dozen Big Pharma and biotech companies have GLP-1